Avutometinib (VS-6766) + Defactinib (VS-6063)
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Low Grade Serous Ovarian Cancer
Conditions
Low Grade Serous Ovarian Cancer, Ovarian Cancer
Trial Timeline
Oct 30, 2024 → Oct 1, 2027
NCT ID
NCT06682572About Avutometinib (VS-6766) + Defactinib (VS-6063)
Avutometinib (VS-6766) + Defactinib (VS-6063) is a phase 2 stage product being developed by Verastem Oncology for Low Grade Serous Ovarian Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06682572. Target conditions include Low Grade Serous Ovarian Cancer, Ovarian Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06682572 | Phase 2 | Active |
Competing Products
20 competing products in Low Grade Serous Ovarian Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [203Pb]VMT-α-NET | Perspective Therapeutics | Phase 1 | 25 |
| azenosertib | Zentalis Pharmaceuticals | Phase 2 | 44 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 44 |
| DS-1001b | Daiichi Sankyo | Phase 2 | 52 |
| Rabeprazole Sodium | Eisai | Pre-clinical | 23 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 52 |
| Abemaciclib + Letrozole | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib + Mosunetuzumab | Eli Lilly | Phase 2 | 52 |
| Pembrolizumab + Pemetrexed + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| DSP-0390 | Sumitomo Pharma | Phase 1 | 33 |
| Mirvetuximab soravtansine + Carboplatin | AbbVie | Phase 2 | 52 |
| Mirvetuximab Soravtansine | AbbVie | Phase 2 | 52 |
| Acalabrutinib + Obinutuzumab | AstraZeneca | Phase 2 | 52 |
| Olaparib Pill + AZD6738 | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Efineptakin alfa + Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel | Merck | Phase 2 | 52 |
| Cilengitide | Merck | Phase 2 | 52 |
| Avelumab | Merck | Phase 2 | 52 |